CRF-R1 Antagonist Treatment Exacerbates Circadian Corticosterone Secretion under Chronic Stress, but Preserves HPA Feedback Sensitivity.

CRF CRF receptor type 1 antagonist HPA axis antidepressant anxiety chronic stress depression glucocorticoids

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
08 Dec 2021
Historique:
received: 03 11 2021
revised: 01 12 2021
accepted: 04 12 2021
entrez: 28 12 2021
pubmed: 29 12 2021
medline: 29 12 2021
Statut: epublish

Résumé

Despite promising initial reports, corticotropin-releasing factor receptor type-1 (CRF-R1) antagonists have mostly failed to display efficacy in clinical trials for anxiety or depression. Rather than broad-spectrum antidepressant/anxiolytic-like drugs, they may represent an 'antistress' solution for single stressful situations or for patients with chronic stress conditions. However, the impact of prolonged CRF-R1 antagonist treatments on the hypothalamic-pituitary-adrenal (HPA) axis under chronic stress conditions remained to be characterized. Hence, our study investigated whether a chronic CRF-R1 antagonist (crinecerfont, formerly known as SSR125543, 20 mg·kg

Identifiants

pubmed: 34959395
pii: pharmaceutics13122114
doi: 10.3390/pharmaceutics13122114
pmc: PMC8707167
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Psychopharmacology (Berl). 2017 May;234(9-10):1467-1481
pubmed: 28265716
Proc Natl Acad Sci U S A. 1996 Sep 17;93(19):10477-82
pubmed: 8816826
J Pharmacol Exp Ther. 2002 Apr;301(1):322-32
pubmed: 11907190
Mol Psychiatry. 2004 Mar;9(3):278-86, 224
pubmed: 14699428
Soc Sci Med. 1988;26(3):333-41
pubmed: 3279522
Prog Neuropsychopharmacol Biol Psychiatry. 2003 Jun;27(4):625-31
pubmed: 12787849
Am J Psychiatry. 1995 Sep;152(9):1372-6
pubmed: 7653697
Biol Psychiatry. 2007 Jul 1;62(1):47-54
pubmed: 17123470
Horm Behav. 2004 Jan;45(1):10-22
pubmed: 14733887
Pharmacol Biochem Behav. 2011 May;98(3):425-31
pubmed: 21356230
J Pharmacol Exp Ther. 2004 Apr;309(1):293-302
pubmed: 14742750
Physiol Behav. 2019 Feb 1;199:229-243
pubmed: 30468744
Psychopharmacology (Berl). 1998 Jul;138(1):55-66
pubmed: 9694527
Neuroendocrinology. 1994 Oct;60(4):436-44
pubmed: 7824085
Neurobiol Stress. 2020 Dec 24;14:100286
pubmed: 33392367
J Psychiatr Res. 2003 Nov-Dec;37(6):525-33
pubmed: 14563384
Eur J Pharmacol. 2004 Aug 16;497(1):49-53
pubmed: 15321734
Behav Brain Res. 2015 Feb 15;279:41-6
pubmed: 25446760
J Clin Endocrinol Metab. 2021 Oct 15;:
pubmed: 34653252
J Psychiatr Res. 2000 May-Jun;34(3):171-81
pubmed: 10867111
Peptides. 2001 May;22(5):835-44
pubmed: 11337098
Pharmacol Biochem Behav. 2004 Mar;77(3):465-9
pubmed: 15006456
Nat Neurosci. 2003 Oct;6(10):1100-7
pubmed: 12973355
Neuropsychobiology. 2016;73(3):184-90
pubmed: 27221315
Neuropsychopharmacology. 2007 Sep;32(9):1941-9
pubmed: 17287823
Pharmacol Biochem Behav. 2012 Sep;102(3):415-22
pubmed: 22659580
Psychopharmacology (Berl). 2002 Dec;165(1):86-92
pubmed: 12474122
Behav Neurosci. 1986 Oct;100(5):669-74
pubmed: 3022767
Psychopharmacology (Berl). 2013 Jul;228(1):97-107
pubmed: 23407783
Front Neuroanat. 2017 Jul 25;11:63
pubmed: 28790896
Br J Pharmacol. 2015 Aug;172(16):4066-77
pubmed: 25989383
Curr Protoc Pharmacol. 2013 Jun;Chapter 5:Unit 5.65
pubmed: 23744712
Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jan 10;40:213-20
pubmed: 23367508
J Pharmacol Exp Ther. 2002 Apr;301(1):333-45
pubmed: 11907191
Neuropharmacology. 2011 Jun;60(7-8):1135-41
pubmed: 20951149
Proc Natl Acad Sci U S A. 2019 Feb 12;116(7):2733-2742
pubmed: 30683720
Neuropsychopharmacology. 2009 May;34(6):1363-80
pubmed: 18536703
Mol Psychiatry. 2015 Feb;20(1):32-47
pubmed: 25486982
Neuron. 2020 Apr 22;106(2):301-315.e7
pubmed: 32101698
J Physiol. 1998 Jul 15;510 ( Pt 2):605-14
pubmed: 9706007
Therapie. 1993 Sep-Oct;48(5):421-6
pubmed: 8146818
Brain Res. 2002 Oct 18;952(2):188-99
pubmed: 12376179
J Psychosom Res. 2002 Oct;53(4):865-71
pubmed: 12377295
Biol Psychiatry. 2008 Aug 15;64(4):293-301
pubmed: 18406399
J Pharmacol Exp Ther. 2000 Aug;294(2):588-97
pubmed: 10900236
Psychoneuroendocrinology. 2001 Jul;26(5):443-59
pubmed: 11337130
Gen Comp Endocrinol. 2003 Feb 15;130(3):267-78
pubmed: 12606269
Cell Signal. 2016 May;28(5):531-540
pubmed: 26898829
J Pharmacol Exp Ther. 2002 Jul;302(1):1-7
pubmed: 12065693
Neuropsychopharmacology. 2003 Dec;28(12):2148-59
pubmed: 12915860
Mol Psychiatry. 2011 Dec;16(12):1177-88
pubmed: 21537331
Annu Rev Physiol. 1986;48:475-94
pubmed: 2871808
Psychoneuroendocrinology. 2016 May;67:113-23
pubmed: 26881837
Neuroendocrinology. 2004 Jan;79(1):1-12
pubmed: 14755129

Auteurs

Yadira Ibarguen-Vargas (Y)

UMR1253, iBrain, Université de Tours, Inserm, 37200 Tours, France.
EUK-CVL, Université d'Orléans, 45100 Orléans, France.

Samuel Leman (S)

UMR1253, iBrain, Université de Tours, Inserm, 37200 Tours, France.

Rupert Palme (R)

Department of Biomedical Sciences/Biochemistry, University of Veterinary Medicine, 1210 Vienna, Austria.

Catherine Belzung (C)

UMR1253, iBrain, Université de Tours, Inserm, 37200 Tours, France.

Alexandre Surget (A)

UMR1253, iBrain, Université de Tours, Inserm, 37200 Tours, France.

Classifications MeSH